Welcome to MedicaMetrix
Lorem ipsum dolor sit amet
IP Acquired
Real time insights
The Unmet Need
The ProstaMetrix Platform enables determination of PSAD, a valuable metric in diagnosing prostate cancer and BPH, as well as Monitoring Prostate Disease in the Doctor's
- Healthcare professionals today are limited to a Digital Rectal Exam (DRE) to determine if the prostate is enlarged or expensive imaging (MRI, UltraSound)
- DREs are subjective and they do not provide reproducible or quantitative measurements of prostate volume
- PSA Tests have a 75% false positive rate and cannot be effectively used on their own to accurately diagnose prostate disease
The ProstaMetrix Solution
Urologists believe that prostate volume is a valuable additional parameter that enhances their ability to diagnose prostate disease
PRECISION CARE FOR PROSTATE HEALTH
The ProstaMetrix Device
To know more about our technology. Send a request now
Key Benefits of Early Prostate Diagnostics
Low Cost
$60 - $90 per procedure
Convenient Access
Easily accessible for clinicians
Early Detection
Helps detect prostate conditions early
Minimally Invasive
Ensures patient comfort and minimal risk
Optimum Standard
Accurate prostate volume measurement
TESTIMONIALS
Voices of Trust and Impact
PAUL A. CHURCH, M.D
DAVID R. STASKIN, M.D.
Raj Persad, M.D.
Investor Opportunities
MedicaMetrix Launches Equity Financing and Investor Portal
MedicaMetrix has initiated a Regulation A, Tier 2 equity financing, inviting public investors to participate in their pre-IPO funding round. They have also launched an online investor portal providing information and resources for both public and accredited investors.
Precision. Protection.
Peace of Mind.
Latest news & articles from the blog.
Questions & answers
Frequently asked questions
1. What is MedicaMetrix?
MedicaMetrix is a medical technology company specializing in innovative solutions for prostate health. Their flagship product, the ProstaMetrix Platform, is designed to detect, diagnose, and monitor prostate diseases efficiently during a single doctor's visit.
2. What is the ProstaMetrix Platform?
The ProstaMetrix Platform enables healthcare professionals to perform Quantitative Digital Rectal Exams (QDRE) to determine prostate volume. It integrates with the ProstaMetrix PSA Test to provide Prostate Density (PSAD) at the time of the initial doctor's visit, facilitating early detection and monitoring of prostate conditions.
3. How does ProstaMetrix improve prostate disease diagnosis?
Traditional methods like Digital Rectal Exams (DRE) are subjective and lack reproducible measurements, while PSA tests have a high false positive rate. ProstaMetrix offers a quantitative approach, providing accurate prostate volume measurements and PSAD, reducing the need for costly MRIs, invasive transrectal ultrasounds (TRUS), and biopsies.
4. What are the benefits of using ProstaMetrix?
- Low Cost: Each procedure costs between $60 - $90.
- Convenient Access: Easily accessible for clinicians.
- Early Detection: Facilitates early detection of prostate conditions.
- Minimally Invasive: Ensures patient comfort with minimal risk.
- Accuracy and Precision: Provides accurate prostate volume measurement
5. How does ProstaMetrix contribute to patient safety?
By reducing unnecessary interventions like MRIs, TRUS, and biopsies, ProstaMetrix minimizes patient exposure to potential complications such as erectile dysfunction and incontinence, enhancing overall patient safety.